From: TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
RR | 95 percent CI | P | RR | 95 percent CI | P | |
Age, ≥55 years versus <55 years | 1.22 | 0.52–2.84 | 0.65 | |||
Tumor type (overall effect) | 0.32 | |||||
Lobular (versus ductal) | 0.65 | 0.28–1.51 | 0.31 | |||
Other (versus ductal) | 0.34 | 0.05–2.53 | 0.29 | |||
Tumor size (overall effect) | 0.014 | |||||
pT2 (versus pT1) | 2.63 | 0.88–7.86 | 0.085 | |||
pT3–pT4 (versus pT1) | 5.27 | 1.61–17.2 | 0.006 | |||
Lymph node status (overall effect) | 0.016 | 0.004 | ||||
pN1 (versus pN0) | 0.45 | 0.16–1.26 | 0.13 | 0.47 | 0.17–1.33 | 0.15 |
pN2–pN3 (versus pN0) | 2.41 | 0.95–6.08 | 0.064 | 3.42 | 1.29–9.05 | 0.013 |
Othera (versus pN0) | 2.12 | 0.75–5.98 | 0.16 | 2.70 | 0.93–7.78 | 0.067 |
Histological grade (overall effect) | 0.68 | |||||
G2 (versus G1) | 2.20 | 0.30–16.3 | 0.44 | |||
G3 (versus G1) | 2.07 | 0.25–16.8 | 0.50 | |||
TP53 mutation (versus wild type) | 3.46 | 1.66–7.21 | 0.002 | 4.43 | 2.04–9.64 | 0.0004 |
ER positive (versus negative) | 0.75 | 0.35–1.63 | 0.48 | |||
PR positive (versus negative) | 0.71 | 0.33–1.51 | 0.38 | |||
Gene expression (overall effect) | 0.006 | |||||
Highly proliferating luminal (versus luminal A) | 6.59 | 1.79–24.3 | 0.005 | |||
Normal like (versus luminal A) | 2.82 | 0.71–11.3 | 0.14 | |||
Basal like (versus luminal A) | 6.93 | 1.79–26.8 | 0.005 | |||
ERRB2+ (versus luminal A) | 5.82 | 1.30–26.2 | 0.022 |